Xing Li

Xing Li is an experienced professional in the field of gene therapy and virology. Currently serving as the Director of MSAT Virology at Ultragenyx since June 2022, Xing Li focuses on major deviation investigations, tech transfers, and managing learning programs related to AAV gene therapy. Prior roles include Head of Vectorology at Sanofi, where responsibilities included leading AAV gene therapy development, and Senior Scientist positions at Takeda and Shire, concentrating on AAV gene therapy and vector production. Xing Li began an academic career at Dana-Farber Cancer Institute, contributing to antiviral protein crystallography and host-virus interaction studies. Xing Li holds a PhD in Molecular and Cell Biology from the University of Maryland Baltimore County.